DK1073639T3 - Chinolinderivater - Google Patents

Chinolinderivater

Info

Publication number
DK1073639T3
DK1073639T3 DK99947036T DK99947036T DK1073639T3 DK 1073639 T3 DK1073639 T3 DK 1073639T3 DK 99947036 T DK99947036 T DK 99947036T DK 99947036 T DK99947036 T DK 99947036T DK 1073639 T3 DK1073639 T3 DK 1073639T3
Authority
DK
Denmark
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
DK99947036T
Other languages
Danish (da)
English (en)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Application granted granted Critical
Publication of DK1073639T3 publication Critical patent/DK1073639T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK99947036T 1998-04-27 1999-04-26 Chinolinderivater DK1073639T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives

Publications (1)

Publication Number Publication Date
DK1073639T3 true DK1073639T3 (da) 2003-03-24

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99947036T DK1073639T3 (da) 1998-04-27 1999-04-26 Chinolinderivater

Country Status (32)

Country Link
EP (1) EP1073639B1 (sr)
JP (1) JP4045069B2 (sr)
KR (1) KR100571534B1 (sr)
CN (1) CN1113057C (sr)
AP (1) AP1293A (sr)
AT (1) ATE228505T1 (sr)
AU (1) AU747550B2 (sr)
BR (1) BR9909925B1 (sr)
CA (1) CA2329788C (sr)
CZ (1) CZ297439B6 (sr)
DE (1) DE69904162T2 (sr)
DK (1) DK1073639T3 (sr)
EE (1) EE04275B1 (sr)
ES (1) ES2188242T3 (sr)
HR (1) HRP20000726B1 (sr)
HU (1) HU227709B1 (sr)
ID (1) ID26277A (sr)
IL (2) IL138160A0 (sr)
IS (1) IS2082B (sr)
ME (1) ME00870B (sr)
NO (1) NO315606B1 (sr)
NZ (1) NZ506641A (sr)
OA (1) OA11547A (sr)
PL (1) PL190441B1 (sr)
PT (1) PT1073639E (sr)
RS (1) RS50029B (sr)
RU (1) RU2197481C2 (sr)
SE (1) SE9801474D0 (sr)
TR (1) TR200003061T2 (sr)
UA (1) UA60354C2 (sr)
WO (1) WO1999055678A1 (sr)
ZA (1) ZA200004601B (sr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
PT1828160E (pt) 2004-12-21 2012-01-05 Merck Serono Sa Derivados cíclicos de sulfonilamino e sua utilização
RS51957B (sr) 2005-01-31 2012-02-29 Merck Serono Sa. Derivati n-hidroksiamida i njihova upotreba
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EA013816B1 (ru) 2005-09-01 2010-08-30 Арес Трейдинг С.А. Лечение неврита зрительного нерва
NZ567088A (en) 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
KR20110048571A (ko) * 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
CA2791711A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물
AU2021229611A1 (en) 2020-03-03 2022-10-27 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor
ES3057099T3 (en) 2021-01-18 2026-02-26 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
AU2022303084A1 (en) 2021-07-02 2024-01-25 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
AU2022421214A1 (en) * 2021-12-20 2024-07-04 The Johns Hopkins University Compounds for treatment of cancer
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SU1735288A1 (ru) * 1990-03-05 1992-05-23 Харьковский государственный фармацевтический институт Способ получени N-R-замещенных амидов 4-гидроксихинолон-2 карбоновой -3-кислоты
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds

Also Published As

Publication number Publication date
PT1073639E (pt) 2003-04-30
NZ506641A (en) 2002-03-28
AP1293A (en) 2004-08-30
ME00870B (me) 2008-11-28
NO315606B1 (no) 2003-09-29
HU227709B1 (en) 2011-12-28
NO20005254L (no) 2000-12-27
HRP20000726A2 (en) 2001-04-30
HK1036618A1 (en) 2002-01-11
HRP20000726B1 (hr) 2009-04-30
BR9909925B1 (pt) 2010-09-21
KR100571534B1 (ko) 2006-04-14
AP2000001933A0 (en) 2000-12-31
AU4301399A (en) 1999-11-16
ATE228505T1 (de) 2002-12-15
BR9909925A (pt) 2001-01-09
WO1999055678A1 (en) 1999-11-04
RS50029B (sr) 2008-11-28
NO20005254D0 (no) 2000-10-19
EE200000613A (et) 2002-04-15
CZ20003849A3 (cs) 2001-03-14
JP2002513006A (ja) 2002-05-08
IS2082B (is) 2006-02-15
ZA200004601B (en) 2002-02-27
PL190441B1 (pl) 2005-12-30
ES2188242T3 (es) 2003-06-16
CN1113057C (zh) 2003-07-02
TR200003061T2 (tr) 2001-01-22
IS5615A (is) 2000-08-31
EP1073639A1 (en) 2001-02-07
RU2197481C2 (ru) 2003-01-27
JP4045069B2 (ja) 2008-02-13
DE69904162D1 (de) 2003-01-09
CN1298393A (zh) 2001-06-06
IL138160A0 (en) 2001-10-31
ID26277A (id) 2000-12-14
EE04275B1 (et) 2004-04-15
UA60354C2 (uk) 2003-10-15
HUP0102084A3 (en) 2002-12-28
HUP0102084A2 (hu) 2001-11-28
IL138160A (en) 2006-04-10
CA2329788C (en) 2004-11-23
OA11547A (en) 2004-05-24
DE69904162T2 (de) 2003-08-21
AU747550B2 (en) 2002-05-16
CZ297439B6 (cs) 2006-12-13
EP1073639B1 (en) 2002-11-27
CA2329788A1 (en) 1999-11-04
SE9801474D0 (sv) 1998-04-27
YU61200A (sh) 2003-07-07
PL343420A1 (en) 2001-08-13

Similar Documents

Publication Publication Date Title
NO20013003D0 (no) Kinolin-derivater
ATE228505T1 (de) Chinolinderivate
ATE250036T1 (de) Chinolinderivate
ATE229005T1 (de) Chinolinderivate
ATE240327T1 (de) 1,2-annelierte chinolinderivate
NO20010193D0 (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
DE69934788D1 (de) Biozide benzylbiphenylderivative
NO20010514L (no) Aminometylkarboksylsyre-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
PT1056716E (pt) Derivados de ciclo-hexanodiolo
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE233253T1 (de) Chromanderivate
ATE281436T1 (de) Chinolin-4-yl-derivate
DK1060183T3 (da) 5-deoxycytidinderivater
PT1123283E (pt) Derivados de tiazole
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate